CSIMarket
 


Sangamo Therapeutics Inc   (SGMO)
Other Ticker:  
 
 

SGMO's Income from Cont. Operations Growth by Quarter and Year

Sangamo Therapeutics Inc 's Income from Cont. Operations results by quarter and year




SGMO Income from Cont. Operations (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December -60.30 -51.97 -37.50 -40.68
III Quarter September -104.16 -53.16 -47.69 -1.51
II Quarter June -114.51 -43.17 -47.17 -35.97
I Quarter March 21.13 -43.98 -45.94 -42.97
FY   -257.84 -192.28 -178.30 -121.13



SGMO Income from Cont. Operations fourth quarter 2023 Y/Y Growth Comment
Sangamo Therapeutics Inc in the fourth quarter 2023 recorded loss from continued operations of $ -60.30 millions.

According to the results reported in the fourth quarter 2023, Sangamo Therapeutics Inc achieved the best Income from Cont. Operations growth in Biotechnology & Pharmaceuticals industry. While Sangamo Therapeutics Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the fourth quarter 2023.




SGMO Income from Cont. Operations ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Sangamo Therapeutics Inc 's fourth quarter 2023 Income from Cont. Operations $ -60.30 millions SGMO's Income Statement
Sangamo Therapeutics Inc 's fourth quarter 2022 Income from Cont. Operations $ -51.97 millions Quarterly SGMO's Income Statement
New: More SGMO's historic Income from Cont. Operations Growth >>


SGMO Income from Cont. Operations (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Sangamo Therapeutics Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


SGMO's IV. Quarter Q/Q Income from Cont. Operations Comment
Even if Sangamo Therapeutics Inc in the IV. Quarter 2023 revealed loss from continued operations of $ -60.30 millions, management said, that this point to slight up side in contrast to the -104.16 millions in the third quarter.

Within Biotechnology & Pharmaceuticals industry Sangamo Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Sangamo Therapeutics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


SGMO's IV. Quarter Q/Q Income from Cont. Operations Comment
Even if Sangamo Therapeutics Inc in the IV. Quarter 2023 showed loss from continued operations of $ -60.30 millions, some analyst point out, that those numbers are improvement compare to the -104.16 millions in the third quarter.

Within Biotechnology & Pharmaceuticals industry Sangamo Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Sangamo Therapeutics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Sangamo Therapeutics Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Income from Cont. Operations 12 Months Ending $ -257.83 $ -249.51 $ -198.50 $ -127.17 $ -192.28
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Sangamo Therapeutics Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -258 millions in the Dec 31 2023 period.
The results are getting worse as the cumulative loss from continued operations is getting bigger from $ -249.51 millions for the period from Sep 30 2023 to Dec 31 2022 and $ -177.801 millions from the TTM period ending Dec 31 2022.

Sangamo Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Sangamo Therapeutics Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -258 millions in the Dec 31 2023 period.
The results are detiriorating as the cumulative loss from continued operations is getting bigger from $ -249.51 millions in TTM ending quarter Sep 30 2023 and $ -177.801 millions for the twelve months ending in the quarter a year ago Katie  K. Johnson told.

Sangamo Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Biotechnology & Pharmaceuticals Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
SGMO's Income from Cont. Operations Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for SGMO's Competitors
Income from Cont. Operations Growth for Sangamo Therapeutics Inc 's Suppliers
Income from Cont. Operations Growth for SGMO's Customers

You may also want to know
SGMO's Annual Growth Rates SGMO's Profitability Ratios SGMO's Asset Turnover Ratio SGMO's Dividend Growth
SGMO's Roe SGMO's Valuation Ratios SGMO's Financial Strength Ratios SGMO's Dividend Payout Ratio
SGMO's Roa SGMO's Inventory Turnover Ratio SGMO's Growth Rates SGMO's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Dec 31 2023
Conmed Corporation24.40%$ 24.402 millions
The Pennant Group Inc 22.84%$ 22.837 millions
Inmode Ltd 22.54%$ 22.535 millions
Option Care Health Inc 20.30%$ 20.299 millions
Vertex Pharmaceuticals Inc18.31%$ 18.305 millions
Avenue Therapeutics Inc 17.75%$ 17.748 millions
Steris Plc14.29%$ 14.287 millions
Medpace Holdings Inc 14.02%$ 14.021 millions
Zoetis Inc 13.70%$ 13.696 millions
Eli Lilly And Company13.01%$ 13.005 millions
Idexx Laboratories Inc12.96%$ 12.958 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com